

**TORRENT
PHARMA**

CIN: L24230GJ1972PLC002126
 Website: www.torrentpharma.com
 Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office: "Avirat", Thaltej Shilaj Road,
 Ahmedabad - 380059, Gujarat, India.
 Ph.: + 91 79 26599000
 Fax: + 91 79 26582100

**Extract of Consolidated audited financial results
 for the quarter and year ended March 31, 2026**

[₹ in crores]

Particulars	Quarter Ended March 31, 2026	Year Ended March 31, 2026	Quarter Ended March 31, 2025
	(Refer Note 2)		(Refer Note 2)
Total income from operations	4197	13980	2959
Net Profit / (Loss) for the period before tax and exceptional items	595	2961	689
Net Profit / (Loss) for the period before tax and after exceptional items	529	2872	665
Net Profit / (Loss) for the period after tax and exceptional items	364	2138	498
Total comprehensive income	278	1958	534
Paid up equity share capital	169.23	169.23	169.23
Other equity excluding revaluation reserve*		8220	
Earnings per share (Face value of ₹5 each) (Not annualised):			
Basic (in ₹)	11.51	63.92	14.71
Diluted (in ₹)	11.51	63.92	14.71

* Other equity excluding revaluation reserve as on March 31, 2025 was ₹ 7422 crores.

Notes :

1 Summary details of standalone audited financial results of Torrent Pharmaceuticals Limited :
 [₹ in crores]

Particulars	Quarter Ended March 31, 2026	Year Ended March 31, 2026	Quarter Ended March 31, 2025
Total income from operations	2735	10712	2433
Profit before tax	592	2897	622
Profit after tax	467	2192	474
Total comprehensive income	407	2045	469

- 2 Figures for the quarter ended March 31, 2026 and March 31, 2025 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review.
- 3 The Board of Directors in their meeting held on May 22, 2026, proposed a final equity dividend of ₹ 9 per equity share.
- 4 The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2026 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website (URL: www.torrentpharma.com/investors/financial-info/quarterly-results/). The same can be accessed by scanning the QR code provided below.

For **TORRENT PHARMACEUTICALS LIMITED**

Place : Ahmedabad, Gujarat
 Date : May 22, 2026

AMAN MEHTA
 Managing Director
 DIN: 08174906

**TORRENT
PHARMA**

CIN: L24230GJ1972PLC002126
 Website: www.torrentpharma.com
 Email: investorservices@torrentpharma.com

TORRENT PHARMACEUTICALS LIMITED

Registered Office: "Avirat", Thaltej Shilaj Road,
 Ahmedabad – 380059, Gujarat, India.
 Ph.: + 91 79 26599000
 Fax: + 91 79 26582100

**Extract of Consolidated audited financial results
 for the quarter and year ended March 31, 2026**

[₹ in crores]

Particulars	Quarter Ended March 31, 2026	Year Ended March 31, 2026	Quarter Ended March 31, 2025
	(Refer Note 2)		(Refer Note 2)
Total income from operations	4197	13980	2959
Net Profit / (Loss) for the period before tax and exceptional items	595	2961	689
Net Profit / (Loss) for the period before tax and after exceptional items	529	2872	665
Net Profit / (Loss) for the period after tax and exceptional items	364	2138	498
Total comprehensive income	278	1958	534
Paid up equity share capital	169.23	169.23	169.23
Other equity excluding revaluation reserve*		8220	
Earnings per share (Face value of ₹5 each) (Not annualised):			
Basic (in ₹)	11.51	63.92	14.71
Diluted (in ₹)	11.51	63.92	14.71

* Other equity excluding revaluation reserve as on March 31, 2025 was ₹ 7422 crores.

Notes :

1 Summary details of standalone audited financial results of Torrent Pharmaceuticals Limited :

[₹ in crores]

Particulars	Quarter Ended March 31, 2026	Year Ended March 31, 2026	Quarter Ended March 31, 2025
Total income from operations	2735	10712	2433
Profit before tax	592	2897	622
Profit after tax	467	2192	474
Total comprehensive income	407	2045	469

2 Figures for the quarter ended March 31, 2026 and March 31, 2025 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review.

3 The Board of Directors in their meeting held on May 22, 2026, proposed a final equity dividend of ₹ 9 per equity share.

4 The above is an extract of the detailed format of Financial Results for the quarter and year ended March 31, 2026 filed with Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the same, along with the notes, are available on www.nseindia.com, www.bseindia.com and on the Company's website (URL: www.torrentpharma.com/investors/financial-info/quarterly-results/). The same can be accessed by scanning the QR code provided below.

For TORRENT PHARMACEUTICALS LIMITED



Place : Ahmedabad, Gujarat
 Date : May 22, 2026

AMAN MEHTA
 Managing Director
 DIN: 08174906